HemaCare Corporation (OTCBB: HEMA), a leader in cell and tissue collection, processing, and cell therapy solutions, will be presenting and hosting a roundtable discussion at Phacilitate Cell & Gene Therapy World to be held at the Hyatt Regency Miami in Florida, January 17-20. Considered the largest gathering of cell and gene therapy experts in the world, Cell & Gene Therapy forums draw leaders from the pharma and biotech communities interested in the latest innovations in cell therapy.

The presentation, given by Lou Juliano, Senior Vice President of Global Sales and Business Development, and roundtable discussion will focus on the critical factors to maximize allogeneic cell therapy production. The information presented is of key importance to cell therapy researchers who depend on HemaCare as a source for highly pure, viable, and functional cells to develop their therapies.

“As we continue to expand our footprint in support of the cell therapy industry, we recognize a growing need from our customers and prospective partners not simply for quality and consistent cellular raw material alone, but also for collecting this material from donors who meet specific criteria,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “Our expertise in donor selection and management, GMP/GTP-compliant cell collection, as well as handling and logistics places us at the forefront of this cutting-edge science.”

 

Presentation

Date/Time:

   Wednesday, January 18, 2017, 4:50 p.m.

Title:

 Critical factors for allogeneic cell therapy donor management

Speaker:

 Lou Juliano, Senior Vice President, Global Sales & Business Development, HemaCare Corporation
 

Roundtable discussion

Date/Time:

 Thursday, January 19, 2017, 10:50 a.m.

Title:

 Apheresis collection starting material for allogeneic cell therapies: the importance of donor selection and management

Moderator:

 George Eastwood, Vice President, Business Development, HemaCare Corporation
 

About HemaCare

HemaCare specializes in the customization of human-derived biological products and services for customer’s research and cell therapy protocols. HemaCare’s network of FDA-registered, GMP/GTP-compliant collection centers ensures donor material is available for fresh shipment to customers, as well as for internal use within HemaCare’s isolation laboratory. In this laboratory, human biological material such as peripheral blood, bone marrow, and cord blood from donor and patient subjects is isolated into various primary cell types for distribution to customers in fresh and frozen formats. HemaCare’s extensive registry of well-characterized repeat donors provides consistent primary human cells and biological products for advanced biomedical research and cellular therapy process development.

For 39 years, HemaCare has provided human-derived primary blood cells and tissues for biomedical research, supported cell therapy clinical trials and commercialization with apheresis collections, and provided a wide range of consulting services. HemaCare directly supports benchtop immunology and oncology research, compound screening for drug discovery, and assay development and qualification, as well as enables customers to advance both autologous and allogeneic cellular therapies. For more information, please visit www.hemacare.com.